Ursula A. Matulonis, MD, spoke astir the adjacent steps for mirvetuximab soravtansine successful the attraction of patients with folate receptor α–high platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, main of the Division of Gynecologic Oncology, Brock-Wilson Family Chair, and institute doc astatine Dana-Farber Cancer Institute arsenic good arsenic prof of medicine astatine Harvard Medical School successful Boston, Massachusetts, spoke with CancerNetwork® astatine the 2022 Annual Global Meeting of the International Gynecologic Cancer Society astir the aboriginal of mirvetuximab soravtansine successful patients with ovarian cancer.
At the conference, she presented updated findings from the signifier 3 SORAYA proceedings (NCT04296890) which looked astatine mirvetuximab soravtansine monotherapy successful patients with folate receptor α–high platinum-resistant ovarian cancer.1 Additionally, she discussed the upcoming medicine cause idiosyncratic interest enactment (PDUFA) for an support that whitethorn effect from these information and however it could interaction the modular of care.
Transcript:
Mirvetuximab is simply a biomarker-directed therapy. There are precise fewer of those, successful information determination are none, successful the platinum-resistant mounting close now. It’s presently nether reappraisal by the FDA, the PDUFA day is November 28, 2022, for the FDA to marque a decision.2 We’re surely looking guardant to proceeding astir the FDA decision, but mirvetuximab has besides present been tested combined with bevacizumab and is showing fantabulous results. David O’Malley, MD, has been moving that study.3 It’s present being [investigated crossed aggregate studies] combined with carboplatin and besides being utilized a attraction therapy successful the platinum-sensitive, recurrent mounting overall.
References
- Coleman RL, Matulonis U, Lorusso D, et al. Clinical payment of mirvetuximab soravtansine successful ovarian crab patients with precocious folate receptor alpha expression: results from the SORAYA study. Presented at: 2022 Annual Global Meeting of the International Gynecologic Cancer Society; New York, NY; September 29-October 1, 2022. Abstract O028.
- O’Malley D, Oaknin A, Matulonis U, et al. Mirvetuximab soravtansine and bevacizumab successful folate receptor alpha-positive ovarian cancer: efficacy successful patients with and without anterior bevacizumab. Presented at: 2022 Annual Global Meeting of the International Gynecologic Cancer Society; New York, NY; September 29-October 1, 2022. Abstract O011.
English (US)